...
首页> 外文期刊>Cancer Cell International >Identification of potential biomarkers and candidate small molecule drugs in glioblastoma
【24h】

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

机译:胶质母细胞瘤中潜在的生物标志物和候选小分子药物的鉴定

获取原文
           

摘要

Glioblastoma (GBM) is a common and aggressive primary brain tumor, and the prognosis for GBM patients remains poor. This study aimed to identify the key genes associated with the development of GBM and provide new diagnostic and therapies for GBM. Three microarray datasets (GSE111260, GSE103227, and GSE104267) were selected from Gene Expression Omnibus (GEO) database for integrated analysis. The differential expressed genes (DEGs) between GBM and normal tissues were identified. Then, prognosis-related DEGs were screened by survival analysis, followed by functional enrichment analysis. The protein–protein interaction (PPI) network was constructed to explore the hub genes associated with GBM. The mRNA and protein expression levels of hub genes were respectively validated in silico using The Cancer Genome Atlas (TCGA) and Human Protein Atlas (HPA) databases. Subsequently, the small molecule drugs of GBM were predicted by using Connectivity Map (CMAP) database. A total of 78 prognosis-related DEGs were identified, of which10 hub genes with higher degree were obtained by PPI analysis. The mRNA expression and protein expression levels of CETN2, MKI67, ARL13B, and SETDB1 were overexpressed in GBM tissues, while the expression levels of CALN1, ELAVL3, ADCY3, SYN2, SLC12A5, and SOD1 were down-regulated in GBM tissues. Additionally, these genes were significantly associated with the prognosis of GBM. We eventually predicted the 10 most vital small molecule drugs, which potentially imitate or reverse GBM carcinogenic status. Cycloserine and 11-deoxy-16,16-dimethylprostaglandin E2 might be considered as potential therapeutic drugs of GBM. Our study provided 10 key genes for diagnosis, prognosis, and therapy for GBM. These findings might contribute to a better comprehension of molecular mechanisms of GBM development, and provide new perspective for further GBM research. However, specific regulatory mechanism of these genes needed further elaboration.
机译:胶质母细胞瘤(GBM)是一种常见而腐蚀性的原发性脑肿瘤,GBM患者的预后仍然差。本研究旨在识别与GBM开发相关的关键基因,为GBM提供新的诊断和治疗。选自三个微阵列数据集(GSE111260,GSE103227和GSE104267)从基因表达综合分析中选择了基因表达综合症(Geo)数据库。鉴定了GBM和正常组织之间的差异表达基因(DEGS)。然后,通过存活分析筛选预后相关的DEG,然后进行功能性富集分析。构建蛋白质 - 蛋白质相互作用(PPI)网络以探讨与GBM相关的轮毂基因。轮毂基因的mRNA和蛋白表达水平分别使用癌症基因组地图集(​​TCGA)和人蛋白质地图集(HPA)数据库在硅中验证。随后,通过使用连接图(CMAP)数据库预测GBM的小分子药物。通过PPI分析获得了总共78个预后相关的DEG,其中1010个具有更高程度的轮毂基因。 CETN2,MKI67,ARL13B和SETDB1的mRNA表达和蛋白表达水平在GBM组织中过表达,而CALN1,ELAVL3,ADCY3,SYN2,SLC12A5和SOD1的表达水平在GBM组织中下调。另外,这些基因与GBM的预后显着相关。我们最终预测了10个最重要的小分子药物,其可能模仿或反转GBM致癌地位。环丝氨酸和11-脱氧-16,16-二甲基丙原林E2可能被认为是GBM的潜在治疗药物。我们的研究为GBM的诊断,预后和治疗提供了10个关键基因。这些调查结果可能有助于更好地理解GBM发展的分子机制,并为进一步的GBM研究提供新的视角。然而,这些基因的具体调节机制需要进一步阐述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号